<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127721</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0505</org_study_id>
    <secondary_id>NCI-2019-05753</secondary_id>
    <secondary_id>2018-0505</secondary_id>
    <nct_id>NCT04127721</nct_id>
  </id_info>
  <brief_title>Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation</brief_title>
  <official_title>Itacitinib to Prevent Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well itacitinib works in preventing graft versus host disease&#xD;
      in patients with blood disorders undergoing donor stem cell transplantation. A donor&#xD;
      transplantation uses blood-making cells from a family member or unrelated donor to remove and&#xD;
      replace abnormal blood cells. Graft versus host disease is a reaction of the donor's immune&#xD;
      cells against the patient's body. Itacitinib plus standard treatment may help prevent graft&#xD;
      versus host disease in patients who have received a donor stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate the graft-versus (vs.) host disease-free/relapse free survival (GRFS) rate of&#xD;
      itacitinib used as prophylaxis to prevent graft versus host disease (GVHD) after allogeneic&#xD;
      stem cell transplantation (ASCT) at one year.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the time to neutrophil and platelet engraftment and compare between matched and&#xD;
      unmatched donors.&#xD;
&#xD;
      II. To assess safety of itacitinib as measured by non-relapse mortality (NRM) at day 100.&#xD;
&#xD;
      III. To assess the toxicity profile associated with this regimen. IV. To assess the incidence&#xD;
      of acute and chronic GVHD. V. To assess the incidence of disease relapse. VI. To assess the&#xD;
      incidence of non-relapse mortality. VII. To assess overall survival and progression-free&#xD;
      survival. VIII. To assess the incidence of withdrawal syndrome in patients with&#xD;
      myelofibrosis.&#xD;
&#xD;
      TERTIARY OBJECTIVES (CORRELATIVE STUDIES):&#xD;
&#xD;
      I. To study immune recovery and cytokines at various time points pre and post-transplant.&#xD;
&#xD;
      II. To study deoxyribonucleic acid (DNA) damage studies in various cells post-transplant.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING CHEMOTHERAPY: Patients receive busulfan intravenously (IV) over 3 hours on days&#xD;
      -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive itacitinib orally (PO) once daily (QD) on days -21 to 80.&#xD;
      Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day&#xD;
      90. Patients also receive tacrolimus IV then PO twice daily (BID) for 3 months when able, and&#xD;
      methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched&#xD;
      unrelated donor).&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 100 days, 6 months, and 1&#xD;
      year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    0 ACTUAL Enrollment must have Overall Recruitment Status&#xD;
  </why_stopped>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Actual">September 22, 2020</completion_date>
  <primary_completion_date type="Actual">September 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft versus host disease (GVHD)-free/relapse free survival rate</measure>
    <time_frame>At 1 year</time_frame>
    <description>The proportion of patients who are alive without disease relapse of GVHD at one year will be reported, along with the corresponding 95% confidence interval. Logistic regression will be used to assess the association between success and clinical and treatment covariates of interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to day 42</time_frame>
    <description>Will be calculated from the time of transplant and estimated by the Kaplan-Meier method. Distributions will be compared between patients with matched and mismatched donors via the long-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>Up to day 42</time_frame>
    <description>Will be calculated from the time of transplant and estimated by the Kaplan-Meier method. Distributions will be compared between patients with matched and mismatched donors via the long-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of non-relapse mortality</measure>
    <time_frame>At day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the toxicity profile associated with this regimen</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of acute and chronic GVHD.</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease relapse</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be modeled using Cox proportional hazards regression models, considering clinical, demographic, and treatment covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be modeled using Cox proportional hazards regression models, considering clinical, demographic, and treatment covariates of interest. Will be assessed in a competing risks framework, with similar analyses performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess overall survival and progression-free survival.</measure>
    <time_frame>From day of transplant until day of death, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of withdrawal syndrome in patients with myelofibrosis</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune recovery and cytokines</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Generalized linear mixed models will be used to assess the association between cytokines over time and treatment and other factors.</description>
  </other_outcome>
  <other_outcome>
    <measure>Deoxyribonucleic acid (DNA) damage studies</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The proportion of patients with DNA damage will be reported, and generalized logistic mixed models may be used to assess the association with similar covariates.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Allogeneic Stem Cell Transplant Recipient</condition>
  <condition>Hematologic and Lymphocytic Disorder</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING CHEMOTHERAPY: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.&#xD;
ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.&#xD;
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD on days -21 to 80. Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day 90. Patients also receive tacrolimus IV then PO BID for 3 months when able, and methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched unrelated donor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo ASCT</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>INCB 039110</other_name>
    <other_name>INCB-039110</other_name>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Karnofsky performance status of at least 70&#xD;
&#xD;
          -  Patients with hematological disorders undergoing ASCT with conditioning regimen of&#xD;
             timed sequential busulfan and fludarabine&#xD;
&#xD;
          -  Human leukocyte antigen (HLA)-identical sibling or 8/8 matched unrelated donor&#xD;
             available&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks (3 months)&#xD;
&#xD;
          -  Direct bilirubin not greater than 1 mg/dL&#xD;
&#xD;
          -  Alanine transaminase (ALT) less than or equal 3 x upper limit of normal range&#xD;
&#xD;
          -  Serum creatinine less than 1.5 x the upper limit of normal range and creatinine&#xD;
             clearance greater than 50 ml/min&#xD;
&#xD;
          -  Diffusing capacity for carbon monoxide (DLCO) 65% of predicted corrected for&#xD;
             hemoglobin&#xD;
&#xD;
          -  Left ventricle ejection fraction (LVEF) of at least 50%&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of study drug. Post-menopausal women (defined as no&#xD;
             menses for at least 1 year) and surgically sterilized women are not required to&#xD;
             undergo a pregnancy test&#xD;
&#xD;
          -  Subjects (men and women) of childbearing potential must agree to use adequate&#xD;
             contraception beginning at the signing of the informed consent until at least 30 days&#xD;
             after the last dose of study drug. The definition of adequate contraception will be&#xD;
             based on the judgment of the principal investigator or a designated associate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a comorbidity score &gt; 3. The principal investigator is the final arbiter&#xD;
             of eligibility and enrollment of patients with comorbidity score &gt; 3 and may permit&#xD;
             enrollment of these patients on individual basis&#xD;
&#xD;
               -  Active or clinically significant cardiac disease including:&#xD;
&#xD;
                    -  Congestive heart failure New York Heart Association (NYHA) &gt; class II&#xD;
&#xD;
                    -  Active coronary artery disease&#xD;
&#xD;
                    -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta&#xD;
                       blockers or digoxin&#xD;
&#xD;
                    -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months&#xD;
                       before transplant, or myocardial infarction within 6 months before&#xD;
                       transplant&#xD;
&#xD;
          -  Patients with uncontrolled infections&#xD;
&#xD;
          -  Patients with active hepatitis B and C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uday R Popat</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

